SCHEMBL6733246

SCHEMBL6733246

C[C@@H]1CN(C(=O)O)C[C@H](C)N1CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.52
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
KMT2A Q03164 2/20 0.47
MAPK1 P28482 2/20 0.46
HSD17B10 Q99714 4/20 0.45
HPGD P15428 2/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733250 1.00 TP53 (0.52) TP53ALDH1A1KDM4ETDP1KMT2A
SCHEMBL7662902 0.82 TP53 (0.46) TP53ALDH1A1KDM4ETDP1KMT2A
SCHEMBL7662904 0.78 KDM4E (0.46) TP53ALDH1A1KDM4ETDP1KMT2A
SCHEMBL6738932 0.77 TP53 (0.47) TP53ALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL7985669 0.74 SIGMAR1 (0.58) ALDH1A1KDM4ETDP1MAPK1TSHR
SCHEMBL7985675 0.74 SIGMAR1 (0.58) ALDH1A1KDM4ETDP1MAPK1TSHR
SCHEMBL17219336 0.74 LMNA (0.58) TP53ALDH1A1KMT2AHSD17B10GAA
SCHEMBL4832341 0.73 BRD4 (0.48) ALDH1A1HPGDSMN1; SMN2TSHRLMNA
SCHEMBL21192862 0.73 TP53 (0.42) TP53ALDH1A1KDM4ETDP1KMT2A
SCHEMBL15956728 0.71 TEAD3 (0.46) ALDH1A1KDM4EKMT2AGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058905-A1 Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes PFIZER INC. 2004-03-25 US disclosed
US-6686357-B1 BENZIMIDAZOLO-PIPERIDINE COMPOUND PFIZER, INC. 2004-02-03 US disclosed
US-6509464-B1 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation PFIZER INC 2003-01-21 US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 EP disclosed
EP-1098894-A1 FKBP INHIBITORS Pfizer Limited (GB) 2001-05-16 EP disclosed
US-6166011-A FKBP inhibitors PFIZER INC (US) 2000-12-26 US disclosed
WO-2000005231-A1 FKBP INHIBITORS PFIZER LIMITED (GB) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058905-A1 Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes FKBP1A, FKBP4, FKBP1B TP53 363/4885ALDH1A1 983/4885KDM4E 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.